Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes

Carcinogenesis

Volumn 29, Issue 10, 2008, Pages 1955-1962

  Figueroa, Jonine D ^a   Malats, Núria ^b,j   García Closas, Montserrat ^a   Real, Francisco X ^c,d,j   Silverman, Debra ^a   Kogevinas, Manolis ^b,e   Chanock, Stephen ^a   Welch, Robert ^a   Dosemeci, Mustafa ^a   Lan, Qing ^a   Tardón, Adonina ^g   Serra, Consol ^d   Carrato, Alfredo ^h   García Closas, Reina ⁱ   Castaño Vinyals, Gemma ^b,c,f   Rothman, Nathaniel ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^c INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^d UNIVERSITAT POMPEU FABRA   (Spain)

^e UNIVERSITY OF CRETE   (Greece)

^f CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^g UNIVERSITY OF OVIEDO   (Spain)

^h Elche University Hospital   (Spain)

ⁱ HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^j Centro Nacional de Investigaciones Oncológicas   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALDO KETO REDUCTASE 1C3; AROMATIC AMINE; AROMATIC HYDROCARBON RECEPTOR; AROMATIC HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATING PROTEIN; AROMATIC HYDROCARBON RECEPTOR REPRESSOR; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 3A4; EPOXIDE HYDROLASE; EPOXIDE HYDROLASE 1; EPOXIDE HYDROLASE 2; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A4; MYELOPEROXIDASE; ONCOPROTEIN; POLYCYCLIC AROMATIC HYDROCARBON; RECEPTOR BLOCKING AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE QUINONE 1; SULFOTRANSFERASE; SULFOTRANSFERASE 1A1; SULFOTRANSFERASE 1A2; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER RISK; CONTROLLED STUDY; FEMALE; GENE ACTIVATION; GENE FUNCTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION;

3-HYDROXYSTEROID DEHYDROGENASES; ADULT; AGED; AGED, 80 AND OVER; ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENOTYPE; GLUTATHIONE TRANSFERASE; HAPLOTYPES; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); RISK FACTORS; URINARY BLADDER NEOPLASMS; VARIATION (GENETICS);

EID: 53449099969     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgn163     Document Type: Article

References (43)

1. Vineis,P. et al. (1997) Aromatic amines and cancer. Cancer Causes Control, 8, 346-355.
2. Silverman,D.T. et al. (1992) Epidemiology of bladder cancer. Hematol. Oncol. Clin. North Am., 6, 1-30.
3. Pelucchi,C. et al. (2006) Mechanisms of disease: The epidemiology of bladder cancer. Nat. Clin. Pract. Urol., 3, 327-340.
4. Garcia-Closas,M. et al. (2005) NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: Results from the Spanish Bladder Cancer Study and meta-analyses. Lancet, 366, 649-659.
5. Rothman,N. et al. (2007) Commentary: Reflections on G.M. Lower and colleagues' 1979 study associating slow acetylator phenotype with urinary bladder cancer: Meta-analysis, historical refinements of the hypothesis, and lessons learned. Int. J. Epidemiol., 36, 23-28.
6. Hein,D.W. (2002) Molecular genetics and function of NAT1 and NAT2: Role in aromatic amine metabolism and carcinogenesis. Mutat. Res., 506-507, 65-77.
7. Hein,D.W. (2006) N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene, 25, 1649-1658.
8. Boffetta,P. et al. (1997) Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons. Cancer Causes Control, 8, 444-472.
9. Golka,K. et al. (2004) Occupational exposure and urological cancer. World J. Urol., 21, 382-391.
10. Bartsch,H. et al. (1993) Analysis of DNA adducts in smokers' lung and urothelium by 32P-postlabelling: Metabolic phenotype dependence and comparisons with other exposure markers. IARC Sci. Publ., 124 331-340.
11. Zenser,T.V. et al. (2002) Metabolism of N-acetylbenzidine and initiation of bladder cancer. Mutat. Res., 506-507, 29-40.
12. Vineis,P. (1992) Epidemiological models of carcinogenesis: The example of bladder cancer. Cancer Epidemiol. Biomarkers Prev., 1, 149-153.
13. Agundez,J.A. (2004) Cytochrome P450 gene polymorphism and cancer. Curr. Drug Metab., 5, 211-224.
14. Brockmoller,J. et al. (1998) Polymorphisms in xenobiotic conjugation and disease predisposition. Toxicol. Lett., 102-103 173-183.
15. MacLeod,S. et al. (1997) Polymorphisms of CYP1A1 and GSTM1 influence the in vivo function of CYP1A2. Mutat. Res., 376, 135-142.
16. RoosP.H. et al. (2005) Cytochrome P450 interactions in human cancers: New aspects considering CYP1B1. Expert Opin. Drug Metab. Toxicol., 1, 187-202.
17. Joseph,P. et al. (1994) NAD(P)H dehydrogenase, quinone1 (DT-diaphorase): Expression, regulation, and role in cancer. Oncol. Res., 6, 525-532.
18. Palackal,N.T. et al. (2002) Activation of polycyclic aromatic hydrocarbon trans-dihydrodiol proximate carcinogens by human aldo-keto reductase (AKR1C) enzymes and their functional overexpression in human lung carcinoma (A549) cells. J. Biol. Chem., 277, 24799-24808.
19. Penning,T.M. et al. (2000) Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the a1do-keto reductase superfamily: Functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem. J., 351, 67-77.
20. Matsuura,K. et al. (1998) Identification of a principal mRNA species for human 3alpha-hydroxysteroid dehydrogenase isoform (AKR1C3) that exhibits high progtaglandin D2 11-ketoreductase activity. J. Biochem. (Tokyo), 124, 940-946.
21. Nagaraj,N.S. et al. (2006) Cigarette smoke condensate induces cytochromes P450 and aldo-keto reductases in oral cancer cells. Toxicol. Lett., 165, 182-194.
22. Lau,Q. et al. (2004) Oxidative damage-related genes AKR1C3 and OGG1 modulate risks for lung cancer due to exposure to PAH-rich coal combustion emissions. Carcinogenesis, 25, 2177-2181.
23. Lan,Q. et al. (2007) Genetic polymorphisms in the oxidative stress pathway and susceptibility to non-Hodgkin lymphoma. Hum Genet., 121, 161-168.
24. Cunningham,J.M. et al. (2007) Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol. Biomarkers Prev., 16, 969-978.
25. International HapMap Consortium. (2005) A haplotype map of the human genome. Nature, 437, 1299-1320.
26. Garcia-Closas,M. et al. (2007) Large-scale evaluation of candidate genes identifies associations between VEGF polym-Phisms and bladder cancer risk. PLoS Genet., 3, e29.
27. Carlson,C.S. et al. (2004) Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am. J. Hum. Genet., 74, 106-120.
28. Packer,B.R. et al. (2006) SNP500Cancer: A public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. Nucleic Acids Res., 34 D617-D621.
29. Schaid,D.J. (2004) Evaluating associations of haplotypes with traits. Genet. Epidemiol., 27, 348-364.
30. Benjaminia.H,Y. et al. (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Stat. Methodol., 57, 289-300.
31. Schaid,D.J. et al. (2002) Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am. J. Hum Genet., 70, 425-434.
32. Zhang,H. et al. (2000) Use of classification trees for association studies. Genet. Epidemiol., 19, 323-332.
33. Penning,T.M. et al. (2007) Human aldo-keto reductases: Function, gene regulation, and single nucleofide polymorphisms. Arch. Biochem. Biophys., 464, 241-250.
34. Courter,L.A. et al. (2007) Diesel exhaust influences carcinogenic PAH-induced genotoxicity and gene expression in human breast epithelial cells in culture. Mutat. Res., 625, 72-82.
35. Jakobsson,J. et al. (2007) A novel polymorphism in the 17beta-hydroxysteroid dehydrogenase type 5 (aldo-keto reductase IC3) gene is associated with lower serum testosterone levels in catteasian men. Pharmacogenomics J, 7, 282-289.
36. Chao,C. et al. (2006) NAD(P)H dehydrogenase, quinone 1 (NQ01) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: A meta-analysis. Cancer Epidemiol. Biomarkers Prev., 15, 979-987.
37. Joseph,P. et al. (1994) NAD(P)H dehydrogenase, quirrone 1 (DT diaphorase) specifically prevents the formation of benzo[α]pyrene quinone-DNA adducts generated by cytochrome P4501A1 and P450 reductase. Proc. Natl Acad. Sci. USA, 91, 84la-8417.
38. Sachse,C. et al. (2002) A pharmacogmetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis, 23, 1839-1849.
39. Kuehl,B.L. et al. (1995) Presence of a heterozygms substitution and its relationship to DT-diaphorase activity. Br. J. Cancer, 72, 555-561.
40. Misra,V. et al. (2000) Assessment of the relationship between genotypic status of a DT-diaphorase point mutation and enzymatic activity. Br. J. Cancer, 83, 998-1002.
41. Siegel,D. et al. (1999) Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H dehydrogenase, quinone 1. Pharmacogenetics, 9, 113-121.
42. Brauze,D. et al. (2006) The effect of aryl hydrocarbon receptor ligands on the expression of AhR, AhRR, ARNT, Hiflalpha, CYP1A1 and NQO1 genes in rat liver. Toxicol. Lett., 167, 212-220.
43. Zheng,L. et al. (2003) Sulfotransferase 1A1 (SULT1A1) polymorphism and bladder cancer risk: A case-control study. Cancer Lett., 202, 61-69.